Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 3Wilms Tumor 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Hepatoblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced Rectal Cancer 1

Interventions

Bevacizumab 12olaparib 10Paclitaxel 10Carboplatin 10liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6mirvetuximab soravtansine 4Topotecan 4Taxes 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Biopsy 4pembrolizumab 3cediranib 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × irinotecan sucrosofate × 30 days × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡